Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of AiViva Biopharma.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
AiViva Biopharma
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
1300 Bristol St N, Suite 220, Newport Beach, California 92660
Telephone
Telephone
(949) 662-1949
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

AIV001 (axitinib) is a novel intradermally administered product designed for local, prolonged treatment effect for dermatological conditions. Now it has completed phase 1/2 clinical trials for the treatment of patients with nonmelanoma skin cancer.


Lead Product(s): Axitinib

Therapeutic Area: Oncology Product Name: AIV001

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

AIV007 is a novel formulation using our JEL™ Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis.


Lead Product(s): Lenvatinib

Therapeutic Area: Ophthalmology Product Name: AIV007

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 22, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Second clinical trial assessing AIV001 to address unmet needs of skin diseases building on the exploratory efficacy of AIV001 in an earlier trial in wound healing from surgical incision. AIV001 to be tested in patients with superficial or nodular basal cell carcinoma.


Lead Product(s): AIV001

Therapeutic Area: Oncology Product Name: AIV001

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 02, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

AIV001 was shown to be safe and well tolerated after local intradermal treatment of incisional wounds. Reduction in fibrosis was observed from single AIV001 treatment post-wounding.


Lead Product(s): AIV001

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AIV001

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 25, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY